MARKET

KURA

KURA

Kura Oncology Inc
NASDAQ
9.84
-0.01
-0.10%
After Hours: 9.84 0 0.00% 16:16 12/19 EST
OPEN
9.95
PREV CLOSE
9.85
HIGH
10.18
LOW
9.80
VOLUME
4.07M
TURNOVER
--
52 WEEK HIGH
12.49
52 WEEK LOW
5.41
MARKET CAP
856.25M
P/E (TTM)
-3.9709
1D
5D
1M
3M
1Y
5Y
1D
Syndax Pharma: Continuing Execution In AML
Seeking Alpha · 2d ago
Weekly Report: what happened at KURA last week (1208-1212)?
Weekly Report · 4d ago
Kura Oncology Director Faheem Hasnain Reports Disposal of Common Shares
Reuters · 12/10 21:05
Kura Oncology (KURA) Gets a Buy from Jefferies
TipRanks · 12/10 13:45
BTIG Sticks to Their Hold Rating for Kura Oncology (KURA)
TipRanks · 12/10 10:07
Kura Oncology’s Promising Clinical Data and Strategic Partnerships Justify Buy Rating
TipRanks · 12/10 01:55
Analysts’ Top Healthcare Picks: Phreesia (PHR), Wave Life Sciences (WVE)
TipRanks · 12/09 13:30
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Autolus Therapeutics (AUTL)
TipRanks · 12/09 11:50
More
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.

Webull offers Kura Oncology Inc stock information, including NASDAQ: KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.